NCT01199575View on ClinicalTrials.gov

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2015

Study Completion Date

July 19, 2022

Conditions

Chronic Lymphocytic LeukemiaCLL

Interventions

DRUG

Revlimid

DRUG

Rituximab

Trial Locations (1)

92093

University of California, San Diego, La Jolla

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of California, San Diego

OTHER